The sales are routine in size relative to market cap and follow a major acquisition close, likely driven by post-deal portfolio rebalancing rather than fundamental concern. Monitor for any additional insider sales in the next 30 days; a sustained pattern would warrant closer attention. The acquisition integration and debt service remain the key catalysts.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 29 $157.77entry
- T+1 · 6mo ago +1.72%α +1.46% · $160.48
- T+5 · 6mo ago +3.49%α +6.01% · $163.27
- T+20 · 5mo ago +6.82%α +10.45% · $168.52
- T+60 · 3mo ago −3.35%α −4.27% · $152.49
Price Chart
How similar events traded
Executive Summary
Two Neurocrine insiders sold a combined $38.43M in shares over the past week, with Director Kevin Gorman accounting for $37.82M (245.1K shares at $154.33) and the Chief Corporate Affairs Officer selling $609K. The sales follow the May 18 closing of the $2.9B Soleno Therapeutics acquisition, which added $600M in new debt. At 0.24% of market cap ($15.7B), the total sell value is modest and likely reflects portfolio rebalancing or tax planning post-deal, not a bearish signal on the business.
Key Financial Metrics
Key Facts
- Director Kevin Gorman sold 245,100 shares for $37.82M on May 19, 2026.
- Chief Corp. Affairs Officer David Boyer sold 3,888 shares for $609K on May 26, 2026.
- Total insider sales of $38.43M represent ~0.24% of NBIX's $15.7B market cap.
- Sales occurred within 10 days of closing the $2.9B Soleno Therapeutics acquisition, funded in part with $600M in new debt.
- No open-market purchases were reported in the cluster.
Financial Impact
Insider sales of $38.43M, or 0.24% of market cap, below the 0.5% materiality threshold.
Risk Factors
- Post-acquisition integration risk for Soleno's VYKAT XR could pressure near-term earnings.
- Additional $600M in debt increases leverage, though the revolving credit facility provides flexibility.
- Further insider selling without purchases could signal waning confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780006230820 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers